The U.S. Food and Drug Administration on Wednesday authorized updated COVID-19 booster shots from Pfizer/BioNTech and Moderna that target the dominant BA.4 and BA.5 Omicron subvariants, as the government prepares for a broad fall vaccination campaign that could begin within days. The new vaccines also include the original version of the virus targeted by all… Read More U.S. FDA approves coronavirus vaccines engineered for Omicron variant
Moderna sued Pfizer and its German partner BioNTech on Friday for patent infringement in the development of the first COVID-19 vaccine approved in the United States, alleging they copied technology that Moderna developed years before the pandemic. Pfizer shares fell nearly 1%, while BioNTech U.S.-listed shares were down about 1.5% and Moderna shares slipped 1.7%… Read More Moderna files lawsuit against Pfizer/BioNTech for patent infringement over coronavirus vaccine
Britain, the first country to approve a coronavirus vaccine in late 2020, has now also given the first green light to a variant-adapted shot that targets both the original and Omicron version of the virus. The UK medicines regulator (MHRA) gave the so-called bivalent vaccine made by U.S. drug company Moderna conditional approval as a… Read More Britain approves vaccine to tackle Omicron coronavirus variant
Moderna Inc said on Friday Swiss drugs regulator Swissmedic had authorized the use of its COVID-19 vaccine for children aged 6 to 11 years. The approval is for the vaccine’s two-dose series of 50 micro gram per dose, Moderna added.
Moderna Inc’s coronavirus vaccine on Friday became the second to receive emergency use authorization (EUA) from the U.S. Food and Drug Administration, welcome news to a nation with a staggering COVID-19 death toll of over 307,000 lives lost. Millions of doses of the Moderna vaccine are expected to be added to the U.S. rollout, which… Read More U.S. FDA approves Moderna’s coronavirus vaccine for emergency use